Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MGLL | Q99685 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25092918 | 0.95 | HRH3 (0.64) | HRH3SIGMAR1MAPTNPSR1POLB | |
| SCHEMBL12765222 | 0.89 | SIGMAR1 (0.70) | HRH3SIGMAR1POLBHRH1 | |
| SCHEMBL24022514 | 0.85 | SIGMAR1 (0.60) | HRH3SIGMAR1POLBL3MBTL3ALDH1A1 | |
| SCHEMBL13164030 | 0.82 | HRH3 (1.00) | HRH3SIGMAR1MAPTNPSR1HRH1 | |
| SCHEMBL10211758 | 0.82 | HRH3 (0.92) | HRH3SIGMAR1MAPTNPSR1HRH1 | |
| SCHEMBL28105315 | 0.82 | SIGMAR1 (0.60) | HRH3SIGMAR1POLBL3MBTL3LMNA | |
| SCHEMBL25042302 | 0.81 | SIGMAR1 (0.65) | HRH3SIGMAR1POLBL3MBTL3 | |
| SCHEMBL24351544 | 0.81 | SIGMAR1 (0.70) | HRH3SIGMAR1MAPTPOLBL3MBTL3 | |
| SCHEMBL22711455 | 0.81 | SIGMAR1 (0.60) | HRH3SIGMAR1POLBL3MBTL3 | |
| SCHEMBL5253680 | 0.81 | SIGMAR1 (0.60) | HRH3SIGMAR1POLBL3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4140485-A1 | MODULATORS OF TOLL-LIKE RECEPTORS FOR THE TREATMENT OF HIV | Gilead Sciences, Inc. (US) | 2023-03-01 | — | — | EP | disclosed |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | NOVARTIS AG (CH) | 2021-12-02 | — | — | US | disclosed |
| WO-2020154474-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-10442812-B2 | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2019-10-15 | — | — | US | disclosed |
| US-10301267-B2 | Compounds | ASTRAZENECA AB (SE) | 2019-05-28 | — | — | US | disclosed |
| US-20190152980-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2019023468-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| US-10040799-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180037586-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | NORTHWESTERN UNIVERSITY (US) | 2018-02-08 | — | — | US | disclosed |
| US-9802942-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | NORTHWESTERN UNIVERSITY (US) | 2017-10-31 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | GLAXOSMITHKLINE LLC | 2008-07-31 | — | — | US | disclosed |
| WO-2008092049-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-31 | — | — | WO | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | US | disclosed |
| US-6946279-B2 | THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS FOR PRODUCING THE SAME | FUJIMORI KOGYO CO., LTD. (JP) | 2005-09-20 | — | — | US | disclosed |
| WO-2005077885-A1 | RUTHENIUM-CATALYZED HYDROAMINATION OF OLEFINS | YALE UNIVERSITY (US) | 2005-08-25 | — | — | WO | disclosed |
| US-20040096953-A1 | Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing composition, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same, | JNC CORPORATION (JP) | 2004-05-20 | — | — | US | disclosed |
| EP-1371663-A1 | THROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, ANHYDROTHROMBIN DERIVATIVES AND PROCESS FOR PRODUCING THE SAME, PLATELET AGGLUTINATION-INDUCING COMPOSITIONS, METHOD OF INDUCING PLATELET AGGLUTINATION, CLINICAL TEST REAGENTS, CLINICAL TEST METHOD, THROMBOSIS INHIBITORS, ADSORBENT AND PROCESS | FUJIMORI KOGYO CO., LTD. (JP) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182852-A1 | ANTHRANILAMIDE INHIBITORS OF AURORA KINASE | AURKA, AURKC, AURKB | HRH3 538/4885SIGMAR1 4602/4885MAPT 2387/4885 |
| US-10040799-B2 | Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GBA2, GBA3 | HRH3 3401/4885SIGMAR1 2576/4885MAPT 1321/4885 |
| US-10301267-B2 | Compounds | SLC10A1, CYP11B1, ABCB11 | HRH3 3986/4885SIGMAR1 2339/4885MAPT 2665/4885 |
| US-20180037586-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | HRH3 3401/4885SIGMAR1 2576/4885MAPT 1321/4885 |
| US-20040096953-A1 | Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing composition, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same, | FGB, F2, TFPI | HRH3 2755/4885SIGMAR1 4882/4885MAPT 3472/4885 |
| US-20080153812-A1 | Heterocyclic amides as anticancer agents | HDAC1, HDAC11, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 1893/4885SIGMAR1 1976/4885MAPT 3682/4885 |
| US-20190152980-A1 | SUBSTITUTED 4-METHYL-PYRROLO[1,2-A]PYRIMIDINE-8-CARBOXAMIDE COMPOUNDS AND USES THEREOF FOR MODULATING GLUCOCEREBROSIDASE ACTIVITY | GBA1, GBA2, GBA3 | HRH3 3401/4885SIGMAR1 2576/4885MAPT 1321/4885 |
| US-20210369716-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | TYR, TBCA, MAPT | HRH3 1033/4885SIGMAR1 4492/4885MAPT 3/4885 |
| US-10442812-B2 | Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity | GBA1, GBA2, GBA3 | HRH3 3401/4885SIGMAR1 2576/4885MAPT 1321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.